Generic placeholder image

Current Psychopharmacology

Editor-in-Chief

ISSN (Print): 2211-5560
ISSN (Online): 2211-5579

Clinical Trial

Omega-3 as an Adjunctive Therapy of Sertraline and Venlafaxine Substantially Improves Symptoms of Major Depressive Disorder: A Double-blind, Placebo-controlled Study

Author(s): Mohammad A. Moghaddam, Malihe Farid, Mahboobeh M. Natanzi, Zohre Khodaii, Rahim Badrfam and Atefeh Zandifar*

Volume 10 , Issue 3 , 2021

Published on: 12 July, 2021

Page: [244 - 250] Pages: 7

DOI: 10.2174/2211556010666210712185437

Price: $65

Abstract

Background: Due to the possible effect of omega-3 fatty acids on reducing depressive symptoms, in this study, we investigated these effects in combination with other antidepressants.

Methods: The study was a double-blind clinical trial on 100 patients with a major depressive disorder who were divided into four groups of 25 each and treated with 50 mg daily sertraline plus placebo, 50 mg daily sertraline plus two grams Omega 3 daily, 75 mg daily venlafaxine plus placebo, and 75 mg daily venlafaxine plus 2 g Omega 3 daily for 6 weeks.

Results: The mean Hamilton depression rating score of sertraline and venlafaxine plus omega-3 after treatment was 4.42 and 4.23 respectively versus sertraline and venlafaxine plus placebo 14.4 and 14.2 respectively (P value=0.0001).

Conclusion: Omega-3 enhanced the clinical function of sertraline and venlafaxine to reduce the severity of depression. Adding omega-3 to either sertraline or venlafaxine does not have a comparative advantage over each other in terms of the improvement of severity of depressive symptoms.

Keywords: Major depression disorder, omega 3, sertraline, venlafaxine, adjunctive therapy, placebo-controlled study.

Graphical Abstract

Rights & Permissions Print Export Cite as
© 2022 Bentham Science Publishers | Privacy Policy